samarium has been researched along with Multiple Myeloma in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abruzzese, E; Di Maio, M; Iuliano, F; Trawinska, MM | 1 |
| Abaya, CD; Berenson, JR; Duvivier, H; Mapes, R; Nassir, Y; Patel, R; Swift, RA; Yellin, O | 1 |
| Allred, J; Ansell, SM; Buadi, F; Dingli, D; Dispenzieri, A; Elliott, MA; Gastineau, DA; Gertz, MA; Geyer, SM; Hayman, SR; Hogan, WJ; Inwards, DJ; Johnston, PB; Kumar, SK; Lacy, MQ; Laumann, KM; Litzow, MR; Micallef, IN; Porrata, L; Wiseman, GA | 1 |
| Bares, R; Dohmen, BM; Einsele, H; Kanz, L; Knop, S | 1 |
| Anderson, PM; Ansell, SM; Dispenzieri, A; Elliott, MA; Erlichman, C; Fonseca, R; Gastineau, DA; Gertz, MA; Greipp, PR; Inwards, DJ; Lacy, MQ; Litzow, MR; Lust, JA; Micallef, IN; Porrata, L; Rajkumar, SV; Sloan, JA; Tefferi, A; Wiseman, GA; Witzig, TE | 1 |
| Allison, R; Bartlett, ML; Butler, J; Durrant, S; Kennedy, GA; MacFarlane, DJ; Morton, J; Western, R | 1 |
| Berger, JD; Claringbold, PG; Glancy, RJ; Manning, LS; O'Donoghue, HL; Turner, JH | 1 |
| Coleman, RE | 1 |
1 review(s) available for samarium and Multiple Myeloma
| Article | Year |
|---|---|
How can we improve the treatment of bone metastases further?
Topics: Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Estrogen Antagonists; Female; Forecasting; Humans; Male; Multiple Myeloma; Osteolysis; Osteoporosis; Pain; Palliative Care; Prostatic Neoplasms; Quality of Life; Radioisotope Teletherapy; Randomized Controlled Trials as Topic; Samarium | 1998 |
3 trial(s) available for samarium and Multiple Myeloma
| Article | Year |
|---|---|
A phase I study of samarium lexidronam/bortezomib combination therapy for the treatment of relapsed or refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Drug Administration Schedule; Ethylenediamines; Humans; Maximum Tolerated Dose; Multiple Myeloma; Organophosphonates; Platelet Count; Pyrazines; Radioisotopes; Recurrence; Samarium | 2009 |
A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma.
Topics: Adult; Aged; Bone Marrow; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Organometallic Compounds; Organophosphorus Compounds; Pain; Peripheral Blood Stem Cell Transplantation; Radioisotopes; Radiopharmaceuticals; Radiotherapy Dosage; Salvage Therapy; Samarium; Tissue Distribution; Transplantation Conditioning | 2010 |
A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Multiple Myeloma; Organometallic Compounds; Organophosphorus Compounds; Radioisotopes; Samarium; Stem Cell Transplantation; Tissue Distribution; Transplantation Conditioning | 2005 |
4 other study(ies) available for samarium and Multiple Myeloma
| Article | Year |
|---|---|
153Sm: its use in multiple myeloma and report of a clinical experience.
Topics: Combined Modality Therapy; Diphosphonates; Humans; Isotopes; Multiple Myeloma; Organometallic Compounds; Organophosphorus Compounds; Pain; Radiography; Samarium | 2008 |
153 Samarium-EDTMP in myeloablative dosage followed by a second autotransplantation in patients with relapsed multiple myeloma.
Topics: Fatal Outcome; Graft Survival; Humans; Male; Melphalan; Multiple Myeloma; Organometallic Compounds; Organophosphorus Compounds; Osteolysis; Peripheral Blood Stem Cell Transplantation; Radioisotopes; Radiopharmaceuticals; Salvage Therapy; Samarium; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2004 |
Outcome of myeloablative allogeneic stem cell transplantation in multiple myeloma with a 153Sm-EDTMP-based preparative regimen.
Topics: Adult; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Organometallic Compounds; Organophosphorus Compounds; Radioisotopes; Radionuclide Imaging; Reproducibility of Results; Samarium; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2005 |
Radiopharmaceutical therapy of 5T33 murine myeloma by sequential treatment with samarium-153 ethylenediaminetetramethylene phosphonate, melphalan, and bone marrow transplantation.
Topics: Animals; Bone Marrow Transplantation; Combined Modality Therapy; Female; In Vitro Techniques; Male; Melphalan; Mice; Mice, Inbred C57BL; Multiple Myeloma; Organometallic Compounds; Organophosphorus Compounds; Samarium; Survival Analysis; Tumor Cells, Cultured | 1993 |